You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

fam-trastuzumab deruxtecan-nxki

Showing 26 - 50 of 1,044
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Breast Cancer Trial in Ireland (trastuzumab deruxtecan (T-DXd) (IV))

Not yet recruiting
  • HER2-positive Breast Cancer
  • trastuzumab deruxtecan (T-DXd) (IV)
  • Galway, Connaught, Ireland
  • +4 more
Jan 24, 2023

Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jul 12, 2023

Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors Trial

Active, not recruiting
  • Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors
  • Trastuzumab deruxtecan
  • Duarte, California
  • +75 more
Jul 15, 2022

Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))

Not yet recruiting
  • Breast Cancer
  • Metastatic Breast Cancer
  • Trastuzumab-Deruxtecan (T-DXd)
  • (no location specified)
Sep 20, 2023

Patients Receiving T-DXd for Treatment of HER2+ Unresectable

Not yet recruiting
  • Breast Cancer
  • None (Observational Study)
  • (no location specified)
Oct 20, 2022

Locally Advanced or Metastatic NSCLC Trial in Worldwide (Trastuzumab Deruxtecan, Cisplatin, Carboplatin)

Recruiting
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • Trastuzumab Deruxtecan
  • +4 more
  • Anchorage, Alaska
  • +148 more
Aug 11, 2022

Previously Treated Advanced/Metastatic HER2-positive Breast

Recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Naples, Italy
  • +17 more
Jan 31, 2023

Advanced Colorectal Cancer Trial in Worldwide (DS-8201a 5.4 mg/kg Q3W, DS-8201a 6.4 mg/kg Q3W)

Active, not recruiting
  • Advanced Colorectal Cancer
  • DS-8201a 5.4 mg/kg Q3W
  • DS-8201a 6.4 mg/kg Q3W
  • Louisville, Kentucky
  • +44 more
Jun 10, 2022

Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression Trial in New York, Providence (Nivolumab, Trastuzumab

Not yet recruiting
  • Esophageal Adenocarcinoma
  • +3 more
  • New York, New York
  • +1 more
Jul 28, 2022

PROVIDENCE - Real-world Study in HER2-positive Unresectable or

Not yet recruiting
  • Breast Neoplasms
  • +2 more
    • (no location specified)
    Oct 7, 2022

    Delirium, Neurocognitive Disorders, Mild Cognitive Impairment Trial in United States (HELP, FAM-HELP)

    Not yet recruiting
    • Delirium
    • +9 more
    • HELP
    • FAM-HELP
    • Orange, California
    • +6 more
    Jun 28, 2023

    Advanced or Metastatic Breast Cancer Trial in Worldwide (Trastuzumab deruxtecan, Capecitabine, Paclitaxel)

    Recruiting
    • Advanced or Metastatic Breast Cancer
    • Trastuzumab deruxtecan
    • +3 more
    • Scottsdale, Arizona
    • +343 more
    Jul 22, 2022

    Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • Trastuzumab deruxtecan
    • +9 more
    • Malmö, Sweden
    • +6 more
    Jun 8, 2023

    HER2-positive Early Breast Cancer Trial in Germany (Trastuzumab deruxtecan, Standard-of-Care)

    Not yet recruiting
    • HER2-positive Early Breast Cancer
    • Munich, Bavaria, Germany
    • +11 more
    Jan 19, 2023

    Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

    Not yet recruiting
    • Stomach Neoplasm
    • (no location specified)
    Oct 16, 2023

    HER2-positive Breast Cancer Trial in Coudekerque-Branche

    Recruiting
    • HER2-positive Breast Cancer
      • Coudekerque-Branche, France
        Clinique des Flandres
      Jan 6, 2022

      Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

      Recruiting
      • Metastatic Breast Cancer
      • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
      • Rome, Italy
        Fondazione Policlinico A. Gemelli - IRCCS
      Jun 22, 2023

      Reporting of Antibody-Drug Conjugate Associated Sepsis-related

      Completed
      • Sepsis (SMQ)
      • +2 more
      • Antibody-Drug Conjugate
      • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
      • Changsha, Hunan, China
        Central South University
      Jun 19, 2022

      HER2 Positive Breast Cancer Trial in United States (tucatinib, trastuzumab deruxtecan)

      Recruiting
      • HER2 Positive Breast Cancer
      • Birmingham, Alabama
      • +32 more
      Oct 26, 2022

      NSCLC Trial in Worldwide (Trastuzumab deruxtecan)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Trastuzumab deruxtecan
      • Aurora, Colorado
      • +47 more
      Apr 27, 2022

      Adenocarcinoma, Gastric, Tumor, Breast Trial in Taipei (DS-8201a)

      Completed
      Has Results
      • Adenocarcinoma, Gastric
      • Neoplasm, Breast
      • Taipei, Taiwan
      • +1 more
      Nov 2, 2022

      Brain Metastases, Adult Trial in Durham (Patritumab deruxtecan)

      Not yet recruiting
      • Brain Metastases, Adult
      • Patritumab deruxtecan
      • Durham, North Carolina
        Duke University Medical Center
      Jan 19, 2023

      Breast Cancer Stage IV Trial in Vienna (Datopotamab deruxtecan)

      Recruiting
      • Breast Cancer Stage IV
      • Datopotamab deruxtecan
      • Vienna, Austria
        AKH Universitaetsklinikum Vienna, Department f. Internal medicin
      May 19, 2023

      Breast Cancer; HER2-positive; Metastatic Trial in Worldwide (Trastuzumab deruxtecan, Placebo, Taxane)

      Recruiting
      • Breast Cancer; HER2-positive; Metastatic
      • Trastuzumab deruxtecan
      • +4 more
      • Phoenix, Arizona
      • +329 more
      Jan 10, 2022

      Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ Trial in Worldwide (Trastuzumab deruxtecan)

      Active, not recruiting
      Has Results
      • Adenocarcinoma Gastric Stage IV With Metastases
      • Adenocarcinoma - GEJ
      • Trastuzumab deruxtecan
      • Duarte, California
      • +36 more
      Jan 24, 2022